HM500197 / Hanmi - LARVOL DELTA

HM500197, a Long-Acting Peptide Based Myostatin Inhibitor, Improves Muscle Mass in Obese Mice (OBESITY WEEK 2026) - No abstract available

Preclinical • Obesity

HM500197 Combination with Incretin-Based Therapy Preserves Skeletal Muscle Mass during Weight Loss (OBESITY WEEK 2026) - No abstract available

According to Hanmi Pharmaceutical, HM500197 showed a level of myostatin inhibitory activity similar to that of non-margumab, a muscle-preserving drug, in vitro studies, and did not show inhibitory action against non-target cytokines, confirming high selectivity. (Maeil Business Newpaper) - "Animal experiments showed a better effect of increasing lean fat centered on skeletal muscle than non-margumab, and also showed differentiation in terms of safety...In particular, skeletal muscle mass was increased in a dose-dependent manner in obese mouse models, and muscle loss was reduced and body fat-centered weight loss was confirmed when administered in combination with GLP-1-based drugs."

Preclinical • Obesity

HM500197, a De Novo–Designed Long-Acting Peptide Myostatin Inhibitor, Improves Skeletal Muscle Mass and Body Composition in Diet-Induced Obese Mice (ADA 2026) - "Introduction and Objective: Incretin therapies effectively reduce body weight and improve metabolic parameters but are frequently accompanied by lean mass loss, underscoring inhibition of the myostatin (MSTN)/activin pathway—exemplified by bimagrumab (Bima)—as a rational therapeutic strategy. HM500197 significantly increased skeletal muscle mass relative to Bima and prevented muscle loss during caloric restriction-induced weight reduction, supporting its potential to improve weight loss quality and serve as an optimal combination partner for incretin therapies."

Late-breaking abstract • Preclinical • Metabolic Disorders • Obesity • INHBB

Results from eight studies on two new muscle-building obesity drugs to be presented at the ADA in June [Google translation] (Hanmi Press Release) - "The next-generation muscle-enhancing therapeutic 'LA-MSTN (HM500197),' being unveiled for the first time, is a new pipeline distinct from the existing innovative obesity drug 'LA-UCN2 (HM17321).' With this, Hanmi Pharmaceutical is assessed to have secured two pillars of next-generation drug pipelines in the field of muscle-enhancing obesity treatment. In particular, it is garnering significant anticipation as the development strategy, differentiation points, and preclinical research results of HM500197 are scheduled to be announced for the first time."

Preclinical • Obesity